Search
You're invited to try out the new version of Value Research Online. Click here to begin: https://beta.valueresearchonline.com

Ranbaxy Laboratories

Sector: Healthcare | Industry: Drugs & Pharma
R 859.80 45.80  | 5.63% 131.85% - 36,602.80
NSE Price: Apr 01, 2015 Change R    |  % 1-Year Change P/E Market Cap (R Cr)
NSE Apr 01, 2015 859.80 45.80 5.63% 814.70 814.00 5,415,702 809.45 - 869.70
BSE Apr 01, 2015 859.90 45.80 5.63% 814.90 814.10 308,222 810.30 - 869.00
Exchange & Time Last Price      Day Change Open Prev Close Volume    1-Day Range
SUBSCRIBE TO THE FREE VALUE RESEARCH STOCK INSIGHT NEWSLETTER
6M Average Volume: 1,196,450 P/B: 13.98 NSE Code: RANBAXY
52-Week Range: R 364.90 - 869.70 Dividend Yield: 0.00% BSE Code: 500359
TTM EPS: R -19.07 Book Value: R 61.50 Face Value: R 5
Number of stocks currently recommended as 'Buy' by Value Research Stock Advisor: 38
Price Graph
  • S&P BSE 100


Please wait while we are fetching data...
Are you missing an opportunity to invest in great stocks at low valuations?
There are thousands of listed companies in India and yet only a handful that are worth investing at a particular time and at a particular price.

Our equity team has sifted through hundreds of companies and selected stocks that you should invest in. This list now has 38 stocks on it, and new ones are being added every month. Thousands of our members are using stagnant equity markets to buy great stocks at low prices. Membership of Value Research Stock Advisor is available at a 40% to 60% discount. Learn more and become a member
Key Ratios
Revenue Per Share (R) Earnings Per Share (R) Return on Networth (%)


Please wait
while we are fetching data...


Please wait
while we are fetching data...


Please wait
while we are fetching data...
Annual Ratios (%)
  1-Year 3-Years 5-Years
Growth
Revenue - - -
Net Profit - - -
EPS - - -
Book Value - - -
Average
Operating Margin 8.71 14.15 17.09
Net Margin -7.98 -9.25 -1.57
Return on Networth -29.26 -23.36 -6.29
Return on Investment -1.95 -3.51 5.34
Interim Growth Ratios (%)
  QoQ YoY YTD
Quarterly
Revenue -19.68 -9.51 -
Operating Profit -93.80 -80.32 -
Net Profit -314.07 -545.85 -
EPS -315.24 - -
TTM
Revenue - - -
Operating Profit - - -
Net Profit - - -
EPS - - -
Peer Comparison
  Market Cap
(R Cr)
Revenue
(R Cr)
Net Profit
(R Cr)
Net Margin (%) RoE (%) Price to Book Price to Earnings
Ranbaxy Laboratories 36,602.80 5,759.40 -135.76 -2.08 -29.26 13.98 -
Insider Trades
Date Person  Buy / Sell Transaction
Type
No of Shares Price
(R)   
Value
(R Lakhs)
Mar 16, 2015 Arun Sawhney  Buy ESOP 9,848 808.05 79.58
Mar 16, 2015 Sushil K Patawari  Buy ESOP 3,004 808.05 24.27
Feb 18, 2015 Indrajit Banerjee  Buy ESOP 3,721 706.80 26.30
Jan 30, 2015 Arun Sawhney  Buy ESOP 12,000 702.60 84.31
Jan 30, 2015 Sushil K Patawari  Buy ESOP 6,750 702.60 47.43
Fund Houses invested in the stock
Fund Mar-15 Dec-14 Sep-14 Jun-14 Mar-14
SBI Mutual Fund 0.671 0.603 0.412 0.284 -
Nippon India Mutual Fund 0.296 0.199 - 0.026 0.026
UTI Mutual Fund 0.218 0.230 0.207 0.124 0.025
Aditya Birla Sun Life Mutual Fund 0.210 0.222 0.179 0.102 0.015
ICICI Prudential Mutual Fund 0.091 0.031 0.010 0.081 0.007
L&T Mutual Fund 0.073 0.060 0.047 0.047 0.042
IDFC Mutual Fund 0.067 0.042 0.016 - 0.105
Edelweiss Mutual Fund 0.053 0.008 - - -
IIFL Mutual Fund 0.030 - - - -
Sundaram Mutual Fund 0.013 0.011 0.002 0.003 -
Figures given above are % of equity capital
Review & Analysis
News & Announcements
Contact Information

Company: Ranbaxy Laboratories Ltd.

Address: A-41, Industrial Area Phase V I I I - A, Sahibzada Ajit Singh Nagar, Mohali, Punjab - 160071 | Phone: 91-172 6678666

Email: [email protected]

Website: www.ranbaxy.com

Registrar & Transfer Agent: Alankit Assignments Ltd

Address: Alankit House , 1 E/13,Jhandewala Extension,New Delhi, Alankit House , 1 E/13, Jhandewala Extension | Phone: 91-11-4254 1234 | Fax: 91-11- 4154 3474

Email: [email protected]

Website: www.alankit.com

Essential checks
Altman Z-Score
3.24
Piotroski F-Score
3
Modified C-Score
5
3-Years Price to Earnings
Not available
3-Years Price to Book
0.88
Earnings Yield
EBIT / Enterprise value
-0.44%
PEG
Price / Earnings to growth ratio
Not available